US Pharm. 2023;48(12):4.
Inflammatory bowel disease (IBD) is an umbrella term for chronic inflammatory bowel diseases, with a population prevalence of around 0.5%. The main types of IBD are ulcerative colitis and Crohn’s disease. Unlike irritable bowel syndrome, IBD results in visible damage to the intestinal mucous membrane.
IBD is characterized by intermittent symptoms. Periods of high disease activity are sometimes followed by longer periods of low or no activity. However, the extent to which IBD patients with low disease activity are also at increased risk of serious infections, including sepsis, has been unclear.
A recent study, published in the journal Clinical Gastroenterology and Hepatology, included data on 55,626 individuals diagnosed with IBD. “Serious infections” referred to infections requiring hospitalization.
The results show that during periods of low disease activity but active gastrointestinal inflammation, known as microscopic inflammation, there was an increased risk of being affected by serious infections compared with periods of microscopically healed intestinal mucosa.
In the case of microscopic inflammation, the number of serious infections was 4.62 per 100 people per year. The corresponding figure for microscopically healed mucosa was 2.53. This corresponded to a 59% relative risk increase for residual microscopic gastrointestinal inflammation, adjusted for various confounders.
Interestingly, the results held true even after adjusting for the prescribed IBD medications, and findings were otherwise similar regardless of age group, sex, and level of education.
The study’s first author was Karl Mårild, an associate professor in pediatrics at the University of Gothenburg’s Sahlgrenska Academy and a consultant at the Gastrointestinal and Liver Clinic at Queen Silvia Children’s Hospital in Gothenburg, Sweden.
“We have shown that even during periods of microscopic intestinal inflammation, IBD patients have an increased risk of serious infections, including sepsis, compared to periods when they have a microscopically healed mucosa,” he explained. “This is also true for patients who appear to have low-active disease in clinical terms, but who have microscopic intestinal inflammation beneath the surface.
“The results indicate that achieving a fully healed intestinal mucosa in IBD may reduce the risk of serious infections. This is important, as serious infections currently contribute toward increased morbidity and mortality in both children and adults with IBD.”
The results from the study are based on data from a national cohort (ESPRESSO) with information from Swedish health registers and from the quality register for IBD (SWIBREG) on people in Sweden diagnosed with IBD between 1990 and 2016. This information was linked to data from microscopic intestinal examinations of patients with IBD.
To comment on this article, contact rdavidson@uspharmacist.com.
